UBE3A Human siRNA Oligo Duplex (Locus ID 7337)

Specifications

Product Data
Purity	HPLC purified
Quality Control	Tested by ESI-MS
Sequences	Available with shipment
Stability	One year from date of shipment when stored at -20°C.
# of transfections	Approximately 330 transfections/2nmol in 24-well plate under optimized conditions (final conc. 10 nM).
Note	Single siRNA duplex (10nmol) can be ordered.
Reference Data
RefSeq	NM_000462, NM_130838, NM_130839, NM_001354505, NM_001354506, NM_001354507, NM_001354508, NM_001354509, NM_001354511, NM_001354512, NM_001354513, NM_001354523, NM_001354526, NM_001354538, NM_001354539, NM_001354540, NM_001354541, NM_001354542, NM_001354543, NM_001354544, NM_001354545, NM_001354546, NM_001354547, NM_001354548, NM_001354549, NM_001354550, NM_001354551, NR_148916
Synonyms	ANCR; AS; E6-AP; EPVE6AP; HPVE6A
Components	UBE3A (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each (Locus ID 7337) Included - SR30004, Trilencer-27 Universal Scrambled Negative Control siRNA Duplex - 2 nmol Included - SR30005, RNAse free siRNA Duplex Resuspension Buffer - 2 ml
Summary	This gene encodes an E3 ubiquitin-protein ligase, part of the ubiquitin protein degradation system. This imprinted gene is maternally expressed in brain and biallelically expressed in other tissues. Maternally inherited deletion of this gene causes Angelman Syndrome, characterized by severe motor and intellectual retardation, ataxia, hypotonia, epilepsy, absence of speech, and characteristic facies. The protein also interacts with the E6 protein of human papillomavirus types 16 and 18, resulting in ubiquitination and proteolysis of tumor protein p53. Alternative splicing of this gene results in three transcript variants encoding three isoforms with different N-termini. Additional transcript variants have been described, but their full length nature has not been determined. [provided by RefSeq, Jul 2008]
Performance Guranteed	OriGene guarantees that at least two of the three Dicer-Substrate duplexes in the kit will provide at least 70% or more knockdown of the target mRNA when used at 10 nM concentration by quantitative RT-PCR when the TYE-563 fluorescent transfection control duplex (cat# SR30002) indicates that >90% of the cells have been transfected and the HPRT positive control (cat# SR30003) provides 90% knockdown efficiency. For non-conforming siRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the siRNA kit. To arrange for a free replacement with newly designed duplexes, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled siRNA control (quantitative RT-PCR data required).

*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.